Hoth Therapeutics, Inc., a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company was incorporated in 2017 and is based in New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone646-756-2997
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees2
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Hoth Therapeutics (NASDAQ:HOTH) Frequently Asked Questions
What is Hoth Therapeutics' stock symbol?
Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."
How were Hoth Therapeutics' earnings last quarter?
Hoth Therapeutics Inc (NASDAQ:HOTH) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter. View Hoth Therapeutics' Earnings History.
When is Hoth Therapeutics' next earnings date?
What price target have analysts set for HOTH?
1 brokerages have issued 1-year target prices for Hoth Therapeutics' stock. Their predictions range from $10.00 to $10.00. On average, they anticipate Hoth Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 127.3% from the stock's current price. View Analyst Price Targets for Hoth Therapeutics.
What is the consensus analysts' recommendation for Hoth Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hoth Therapeutics.
Has Hoth Therapeutics been receiving favorable news coverage?
News articles about HOTH stock have been trending negative on Saturday, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hoth Therapeutics earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Hoth Therapeutics.
Are investors shorting Hoth Therapeutics?
Hoth Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totalling 18,300 shares, a decrease of 7.6% from the July 31st total of 19,800 shares. Based on an average trading volume of 20,700 shares, the short-interest ratio is currently 0.9 days. Currently, 0.6% of the company's stock are sold short. View Hoth Therapeutics' Current Options Chain.
Who are some of Hoth Therapeutics' key competitors?
Some companies that are related to Hoth Therapeutics include Cue Biopharma (CUE), Constellation Pharmaceuticals (CNST), GlycoMimetics (GLYC), Tyme Technologies (TYME), Five Prime Therapeutics (FPRX), Nature's Sunshine Products (NATR), Arcturus Therapeutics (ARCT), LifeVantage (LFVN), Osmotica Pharmaceuticals (OSMT), Imprimis Pharmaceuticals (IMMY), Acasti Pharma (ACST), CannTrust (CTST), Applied Therapeutics (APLT), Generex Biotechnology (GNBT) and XOMA (XOMA).
What other stocks do shareholders of Hoth Therapeutics own?
Who are Hoth Therapeutics' key executives?
Hoth Therapeutics' management team includes the folowing people:
- Mr. Robb Knie, Pres, CEO & Director (Age 50)
- Mr. David S. Briones, Chief Financial Officer (Age 43)
- Ms. Jane H. Behrmann, VP of Operations (Age 34)
When did Hoth Therapeutics IPO?
(HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.
When did Hoth Therapeutics' lock-up period expire?
Hoth Therapeutics' lock-up period expired on Wednesday, August 14th. Hoth Therapeutics had issued 1,250,000 shares in its IPO on February 15th. The total size of the offering was $7,000,000 based on an initial share price of $5.60. Since the expiration of Hoth Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
How do I buy shares of Hoth Therapeutics?
Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Hoth Therapeutics' stock price today?
One share of HOTH stock can currently be purchased for approximately $4.40.
How big of a company is Hoth Therapeutics?
Hoth Therapeutics has a market capitalization of $44.35 million. The company earns $-2,500,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Hoth Therapeutics employs 2 workers across the globe.View Additional Information About Hoth Therapeutics.
What is Hoth Therapeutics' official website?
How can I contact Hoth Therapeutics?
Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected]
MarketBeat Community Rating for Hoth Therapeutics (NASDAQ HOTH)
MarketBeat's community ratings are surveys of what our community members think about Hoth Therapeutics and other stocks. Vote "Outperform" if you believe HOTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
